rpl32 Antibody

Ribosomal protein L32 (RPL32) antibodies are critical tools for investigating ribosome biology and cancer mechanisms. Below are research-focused FAQs addressing methodological and conceptual challenges in working with RPL32 antibodies, supported by experimental evidence from peer-reviewed studies and technical validations.

How do I validate RPL32 antibody specificity in Western blotting?

• Method:

  • Use positive controls: Lysates from cell lines with confirmed RPL32 expression (e.g., HeLa, A549, or SUM 1315 BC cells) .

  • Compare observed vs. calculated molecular weight: RPL32 typically migrates at 16–18 kDa (calculated: ~16 kDa) . Deviations may indicate post-translational modifications or nonspecific binding.

  • Include siRNA knockdown controls: Lentiviral RPL32 silencing in SUM 1315 cells reduced protein levels by ~45% , providing a clear specificity benchmark.

Which applications are best suited for RPL32 antibodies?

RPL32 antibodies are validated for:

• Western blot (WB): Dilutions of 1:500–1:2000 yield optimal results in human, mouse, and rat samples .

• Immunohistochemistry (IHC): Demonstrated in breast and lung cancer tissues to show RPL32 upregulation .

• Immunofluorescence (IF): Used to localize RPL32 in cytoplasmic ribosomal clusters .

Critical Note: Antibody performance varies by sample type. For untested species (e.g., primate tissues), homology-based predictions may be required .

How does RPL32 influence cancer progression, and how can this be experimentally interrogated?

• Functional assays:

  • Migration/Invasion: RPL32 knockdown in SUM 1315 breast cancer cells reduced invasion by 60–70% using Transwell assays .

  • Proliferation: In lung cancer, RPL32 silencing decreased cell proliferation by stabilizing p53, as shown in H1299 (p53 null) vs. A549 (p53 wild-type) comparisons .

How to resolve contradictions in RPL32 expression data across studies?

• Potential causes:

  • Tissue-specific isoforms: RPL32 has no known isoforms, but post-translational modifications (e.g., phosphorylation) may alter antibody binding .

  • Antibody batch variability: Compare lot-specific validation data (e.g., Proteintech vs. Boster Bio ).

• Solutions:

  • Use orthogonal methods (RT-qPCR, CRISPR-Cas9 knockout) to confirm protein trends.

  • Standardize protocols: For WB, ensure consistent lysis buffers (e.g., RIPA with protease inhibitors) .

What controls are essential for RPL32 loss-of-function studies?

• Experimental design:

  • Knockdown Validation: Confirm siRNA efficiency via RT-qPCR (≥90% mRNA reduction) and WB (≥45% protein reduction) .

  • Rescue Experiments: Re-express RPL32 in knockdown cells to rule off-target effects.

  • p53 Status: Assess p53 levels, as RPL32’s pro-tumor effects are p53-dependent in lung cancer .